caa a22 4500 445312610 CHVBK 20180317142635.0 cr unu---uuuuu 170323e20111201xx s 000 0 eng 10.1007/s11095-011-0604-5 doi (NATIONALLICENCE)springer-10.1007/s11095-011-0604-5 RNA Interference and Cancer Therapy [Elektronische Daten] [Zhaohui Wang, Donald Rao, Neil Senzer, John Nemunaitis] ABSTRACT: Since its discovery in 1998, RNA interference (RNAi) has revolutionized basic and clinical research. Small RNAs, including small interfering RNA (siRNA), short hairpin RNA (shRNA) and microRNA (miRNA), mediate RNAi effects through either cleavage-dependent or cleavage-independent RNA inducible silencing complex (RISC) effector processes. As a result of its efficacy and potential, RNAi has been elevated to the status of "blockbuster therapeutic” alongside recombinant protein and monoclonal antibody. RNAi has already contributed to our understanding of neoplasia and has great promise for anti-cancer therapeutics, particularly so for personalized cancer therapy. Despite this potential, several hurdles have to be overcome for successful development of RNAi-based pharmaceuticals. This review will discuss the potential for, challenges to, and the current status of RNAi-based cancer therapeutics. Springer Science+Business Media, LLC, 2011 cancer therapy nationallicence delivery nationallicence RNA interference nationallicence Wang Zhaohui Gradalis, Inc., Dallas, Texas, USA aut Rao Donald Gradalis, Inc., Dallas, Texas, USA aut Senzer Neil Gradalis, Inc., Dallas, Texas, USA aut Nemunaitis John Gradalis, Inc., Dallas, Texas, USA aut Pharmaceutical Research Springer US; http://www.springer-ny.com 28/12(2011-12-01), 2983-2995 0724-8741 28:12<2983 2011 28 11095 https://doi.org/10.1007/s11095-011-0604-5 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11095-011-0604-5 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Wang Zhaohui Gradalis, Inc., Dallas, Texas, USA aut NATIONALLICENCE 700 1- Rao Donald Gradalis, Inc., Dallas, Texas, USA aut NATIONALLICENCE 700 1- Senzer Neil Gradalis, Inc., Dallas, Texas, USA aut NATIONALLICENCE 700 1- Nemunaitis John Gradalis, Inc., Dallas, Texas, USA aut NATIONALLICENCE 773 0- Pharmaceutical Research Springer US; http://www.springer-ny.com 28/12(2011-12-01), 2983-2995 0724-8741 28:12<2983 2011 28 11095 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer